Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2007, Article ID 85208, 8 pages
http://dx.doi.org/10.1155/2007/85208
Review Article

PAI-1 is a Critical Upstream Regulator of the TGF-β1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma

1Center for Cell Biology and Cancer Research, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
2Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA

Received 17 November 2006; Accepted 17 January 2007

Academic Editor: Hasan Mukhtar

Copyright © 2007 Cynthia E. Wilkins-Port et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Eide and M. A. Weinstock, “Epidemiology of skin cancer,” in Cancer of the Skin, D. S. Rigel, R. J. Friedman, L. M. Dzubow, D. S. Reintgen, J.-C. Bystryn, and R. Marks, Eds., pp. 47–60, Elsevier, Philadelphia, Pa, USA, 2005. View at Google Scholar
  2. A. Dlugosz, G. Merlino, and S. H. Yuspa, “Progress in cutaneous cancer research,” Journal of Investigative Dermatology Symposium Proceedings, vol. 7, no. 1, pp. 17–26, 2002. View at Publisher · View at Google Scholar
  3. P. Boukamp, “UV-induced skin cancer: similarities-variations,” Journal of the German Society of Dermatology, vol. 3, no. 7, pp. 493–503, 2005. View at Publisher · View at Google Scholar
  4. M. Dans and S. S. Fakharzadeh, “Genetic basis of skin cancer,” in Cancer of the Skin, D. S. Rigel, R. J. Friedman, L. M. Dzubow, D. S. Reintgen, J.-C. Bystryn, and R. Marks, Eds., pp. 15–27, Elsevier, Philadelphia, Pa, USA, 2005. View at Google Scholar
  5. B. R. Smoller, “Squamous cell carcinoma: from precursor lesions to high-risk variants,” Modern Pathology, vol. 19, supplement 2, pp. S88–S92, 2006. View at Publisher · View at Google Scholar
  6. K. Y. Tsai and H. Tsao, “The genetics of skin cancer,” American Journal of Medical Genetics—Part C: Seminars in Medical Genetics, vol. 131 C, no. 1, pp. 82–92, 2004. View at Publisher · View at Google Scholar
  7. R. J. Akhurst and A. Balmain, “Genetic events and the role of TGFβ in epithelial tumour progression,” Journal of Pathology, vol. 187, no. 1, pp. 82–90, 1999. View at Publisher · View at Google Scholar
  8. W. Cui, D. J. Fowlis, S. Bryson et al., “TGFß1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice,” Cell, vol. 86, no. 4, pp. 531–542, 1996. View at Publisher · View at Google Scholar
  9. G. Portella, S. A. Cumming, J. Liddell et al., “Transforming growth factor ß is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion,” Cell Growth and Differentiation, vol. 9, no. 5, pp. 393–404, 1998. View at Google Scholar
  10. R. Derynck, R. J. Akhurst, and A. Balmain, “TGF-β signaling in tumor suppression and cancer progression,” Nature Genetics, vol. 29, no. 2, pp. 117–129, 2001. View at Publisher · View at Google Scholar
  11. C. Go, P. Li, and X.-J. Wang, “Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis,” Cancer Research, vol. 59, no. 12, pp. 2861–2868, 1999. View at Google Scholar
  12. G. Han, S.-L. Lu, A. G. Li et al., “Distinct mechanisms of TGF-ß1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis,” Journal of Clinical Investigation, vol. 115, no. 7, pp. 1714–1723, 2005. View at Publisher · View at Google Scholar
  13. R. R. Allen and P. J. Higgins, “Plasminogen activator inhibitor type-1 expression and the pathophysiology of TGF-β1-incuced epithelial-to-mesechymal transition,” Recent Research Developments in Physiology, vol. 2, pp. 355–366, 2004. View at Google Scholar
  14. O. Rho, L. M. Beltran, I. B. Gimenez-Conti, and J. DiGiovanni, “Altered expression of the epidermal growth factor receptor and transforming growth factor-α during multistage skin carcinogenesis in SENCAR mice,” Molecular Carcinogenesis, vol. 11, no. 1, pp. 19–28, 1994. View at Publisher · View at Google Scholar
  15. S. H. Yuspa, “The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis,” Journal of Dermatological Science, vol. 17, no. 1, pp. 1–7, 1998. View at Publisher · View at Google Scholar
  16. P. O-Charoenrat, P. H. Rhys-Evans, H. Modjtahedi, W. Court, G. Box, and S. Eccles, “Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion,” International Journal of Cancer, vol. 86, no. 3, pp. 307–317, 2000. View at Publisher · View at Google Scholar
  17. P. O-charoenrat, P. H. Rhys-Evans, D. J. Archer, and S. A. Eccles, “C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors,” Oral Oncology, vol. 38, no. 1, pp. 73–80, 2002. View at Publisher · View at Google Scholar
  18. N. Moghal and P. W. Sternberg, “Multiple positive and negative regulators of signaling by the EGF-receptor,” Current Opinion in Cell Biology, vol. 11, no. 2, pp. 190–196, 1999. View at Publisher · View at Google Scholar
  19. J. Zavadil and E. P. Böttinger, “TGF-β and epithelial-to-mesenchymal transitions,” Oncogene, vol. 24, no. 37, pp. 5764–5774, 2005. View at Publisher · View at Google Scholar
  20. J. Zavadil, M. Bitzer, D. Liang et al., “Genetic programs of epithelial cell plasticity directed by transforming growth factor-ß,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6686–6691, 2001. View at Publisher · View at Google Scholar
  21. T. A. Lehman, R. Modali, P. Boukamp et al., “p53 mutations in human immortalized epithelial cell lines,” Carcinogenesis, vol. 14, no. 5, pp. 833–839, 1993. View at Publisher · View at Google Scholar
  22. C. E. Wilkins-Port, J. Freytag, and P. J. Higgins, “TGFβ1/EGF modulate pericellular proteolysis by stimulating collagenolytic activity in pre-malignant human epidermal keratinocytes,” in Proceedings of the Epithelial Mesenchymal Transition (EMT) Conference, vol. 56, p. 31, Vancouver, British Columbia, Canada, October 2005.
  23. C. E. Wilkins-Port and P. J. Higgins, “Regulation of extracellular matrix remodeling following TGFβ1/EGF stimulated EMT in human pre-malignant keratinocytes,” to appear in Cells Tissues Organs.
  24. R. R. Isseroff and D. B. Rifkin, “Plasminogen is present in the basal layer of the epidermis,” Journal of Investigative Dermatology, vol. 80, no. 4, pp. 297–299, 1983. View at Publisher · View at Google Scholar
  25. H. R. Lijnen, “Matrix metalloproteinases and cellular fibrinolytic activity,” Biochemistry, vol. 67, no. 1, pp. 92–98, 2002. View at Google Scholar
  26. P. A. Andreasen, L. Kjøller, L. Christensen, and M. J. Duffy, “The urokinase-type plasminogen activator system in cancer metastasis: a review,” International Journal of Cancer, vol. 72, no. 1, pp. 1–22, 1997. View at Publisher · View at Google Scholar
  27. B. Hundsdorfer, H. F. Zeilhofer, K. P. Bock, P. Dettmar, M. Schmitt, and H. H. Horch, “The prognostic importance of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma,” Mund Kiefer Grsichtschir, vol. 8, no. 3, pp. 173–179, 2004. View at Publisher · View at Google Scholar
  28. E. Bacharach, A. Itin, and E. Keshet, “Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: a mechanism for balancing pericellular proteolysis during angiogenesis,” Blood, vol. 92, no. 3, pp. 939–945, 1998. View at Google Scholar
  29. K. Bajou, V. Masson, R. D. Gerard et al., “The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies,” Journal of Cell Biology, vol. 152, no. 4, pp. 777–784, 2001. View at Publisher · View at Google Scholar
  30. K. Bajou, A. Noël, R. D. Gerard et al., “Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization,” Nature Medicine, vol. 4, no. 8, pp. 923–928, 1998. View at Publisher · View at Google Scholar
  31. Y.-J. Chen, S.-C. Lin, T. Kao et al., “Genome-wide profiling of oral squamous cell carcinoma,” Journal of Pathology, vol. 204, no. 3, pp. 326–332, 2004. View at Publisher · View at Google Scholar
  32. P. Lindberg, A. Larsson, and B. S. Nielsen, “Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin γ-2 chain is an early coordinated event in incipient oral squamous cell carcinoma,” International Journal of Cancer, vol. 118, no. 12, pp. 2948–2956, 2006. View at Publisher · View at Google Scholar
  33. E. Vairaktaris, C. Yapijakis, Z. Serefoglou et al., “Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer,” Oral Oncology, vol. 42, no. 9, pp. 888–892, 2006. View at Publisher · View at Google Scholar
  34. L. Christensen, A. C. Wiborg Simonsen, C. W. Heegaard, S. K. Moestrup, J. A. Andersen, and P. A. Andreasen, “Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas,” International Journal of Cancer, vol. 66, no. 4, pp. 441–452, 1996. View at Publisher · View at Google Scholar
  35. M. Illemann, U. Hansen, H. J. Nielsen et al., “Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1,” American Journal of Clinical Pathology, vol. 122, no. 2, pp. 256–265, 2004. View at Publisher · View at Google Scholar
  36. B. V. Offersen, B. S. Nielsen, G. Høyer-Hansen et al., “The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas,” American Journal of Pathology, vol. 163, no. 5, pp. 1887–1899, 2003. View at Google Scholar
  37. D. Chin, G. M. Boyle, P. G. Parsons, and W. B. Coman, “What is transforming growth factor-beta (TGF-β)?” British Journal of Plastic Surgery, vol. 57, no. 3, pp. 215–221, 2004. View at Publisher · View at Google Scholar
  38. C. H. Streuli, C. Schmidhauser, M. Kobrin, M. J. Bissell, and R. Derynck, “Extracellular matrix regulates expression of the TGF-β1 gene,” Journal of Cell Biology, vol. 120, no. 1, pp. 253–260, 1993. View at Publisher · View at Google Scholar
  39. T. M. Vollberg, M. D. George, and A. M. Jetten, “Induction of extracellular matrix gene expression in normal human keratinocytes by transforming growth factor β is altered by cellular differentiation,” Experimental Cell Research, vol. 193, no. 1, pp. 93–100, 1991. View at Publisher · View at Google Scholar
  40. N. E. Wikner, J. T. Elder, K. A. Persichitte, P. Mink, and R. A. F. Clark, “Transforming growth factor-β modulates plasminogen activator activity and plasminogen activator inhibitor type-1 expression in human keratinocytes in vitro,” Journal of Investigative Dermatology, vol. 95, no. 5, pp. 607–613, 1990. View at Publisher · View at Google Scholar
  41. K. Ahokas, J. Lohi, S. A. Illman et al., “Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-ß1 in Keratinocytes,” Laboratory Investigation, vol. 83, no. 12, pp. 1887–1899, 2003. View at Publisher · View at Google Scholar
  42. N. Johansson, J. Westermarck, S. Leppä et al., “Collagenase 3 (matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor a and transforming growth factor ß,” Cell Growth and Differentiation, vol. 8, no. 2, pp. 243–250, 1997. View at Google Scholar
  43. E.-S. Kim, M.-S. Kim, and A. Moon, “TGF-β-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells,” International Journal of Oncology, vol. 25, no. 5, pp. 1375–1382, 2004. View at Google Scholar
  44. E.-S. Kim, M.-S. Kim, and A. Moon, “Transforming growth factor (TGF)-β in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells,” Cytokine, vol. 29, no. 2, pp. 84–91, 2005. View at Publisher · View at Google Scholar
  45. H.-S. Kim, T. Shang, Z. Chen, S. C. Pflugfelder, and D.-Q. Li, “TGF-β1 stimulates production of gelatinase (MMP-9), collagenases (MMP-1, -13) and stromelysins (MMP-3, -10, -11) by human corneal epithelial cells,” Experimental Eye Research, vol. 79, no. 2, pp. 263–274, 2004. View at Publisher · View at Google Scholar
  46. M. Madlener, C. Mauch, W. Conca, M. Brauchle, W. C. Parks, and S. Werner, “Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing,” Biochemical Journal, vol. 320, no. 2, pp. 659–664, 1996. View at Google Scholar
  47. H. G. Munshi, Y. I. Wu, S. Mukhopadhyay et al., “Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-ß1-induced pericellular collagenolysis,” Journal of Biological Chemistry, vol. 279, no. 37, pp. 39042–39050, 2004. View at Publisher · View at Google Scholar
  48. M. J. Newman, “Transforming growth factor beta and the cell surface in tumor progression,” Cancer and Metastasis Reviews, vol. 12, no. 3-4, pp. 239–254, 1993. View at Publisher · View at Google Scholar
  49. A. B. Roberts, B. K. McCune, and M. B. Sporn, “TGF-β: regulation of extracellular matrix,” Kidney International, vol. 41, no. 3, pp. 557–559, 1992. View at Google Scholar
  50. A. B. Roberts and L. M. Wakefield, “The two faces of transforming growth factor β in carcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8621–8623, 2003. View at Publisher · View at Google Scholar
  51. J. A. Wright, E. A. Turley, and A. H. Greenberg, “Transforming growth factor β and fibroblast growth factor as promoters of tumor progression to malignancy,” Critical Reviews in Oncogenesis, vol. 4, no. 5, pp. 473–492, 1993. View at Google Scholar
  52. T. Sato, M. Iwai, T. Sakai et al., “Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts,” British Journal of Cancer, vol. 80, no. 8, pp. 1137–1143, 1999. View at Publisher · View at Google Scholar
  53. B. D. Sudbeck, P. Baumann, G. J. Ryan et al., “Selective loss of PMA-stimulated expression of matrix metalloproteinase 1 in HaCaT keratinocytes is correlated with the inability to induce mitogen-activated protein family kinases,” Biochemical Journal, vol. 339, no. 1, pp. 167–175, 1999. View at Publisher · View at Google Scholar
  54. L. L. Chen, R. Narayanan, M. S. Hibbs et al., “Altered epidermal growth factor signal transduction in activated Ha-ras- transformed human keratinocytes,” Biochemical and Biophysical Research Communications, vol. 193, no. 1, pp. 167–174, 1993. View at Publisher · View at Google Scholar
  55. P. O-charoenrat, P. H. Rhys-Evans, and S. A. Eccles, “Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck,” Archives of Otolaryngology—Head & Neck Surgery, vol. 127, no. 7, pp. 813–820, 2001. View at Google Scholar
  56. L. J. Windsor, H. Grenett, B. Birkedal-Hansen, M. K. Bodden, J. A. Engler, and H. Birkedal-Hansen, “Cell type-specific regulation of SL-1 and SL-2 genes. Induction of the SL-2 gene but not the SL-1 gene by human keratinocytes in response to cytokines and phorbolesters,” Journal of Biological Chemistry, vol. 268, no. 23, pp. 17341–17347, 1993. View at Google Scholar
  57. S. Chakraborti, M. Mandal, S. Das, A. Mandal, and T. Chakraborti, “Regulation of matrix metalloproteinases: an overview,” Molecular and Cellular Biochemistry, vol. 253, no. 1-2, pp. 269–285, 2003. View at Publisher · View at Google Scholar
  58. N. H. Cho, K. P. Hong, S. H. Hong, S. Kang, K. Y. Chung, and S. H. Cho, “MMP expression profiling in recurred stage IB lung cancer,” Oncogene, vol. 23, no. 3, pp. 845–851, 2004. View at Publisher · View at Google Scholar
  59. J. H. Gill, I. G. Kirwan, J. M. Seargent et al., “MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas,” Neoplasia, vol. 6, no. 6, pp. 777–785, 2004. View at Publisher · View at Google Scholar
  60. M. Krampert, W. Bloch, T. Sasaki et al., “Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin,” Molecular Biology of the Cell, vol. 15, no. 12, pp. 5242–5254, 2004. View at Publisher · View at Google Scholar
  61. O. Rechardt, O. Elomaa, M. Vaalamo et al., “Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines,” Journal of Investigative Dermatology, vol. 115, no. 5, pp. 778–787, 2000. View at Publisher · View at Google Scholar
  62. U. Impola, V. J. Uitto, J. Hietanen et al., “Differential expression of matrilysin-I (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer,” Journal of Pathology, vol. 202, no. 1, pp. 14–22, 2004. View at Publisher · View at Google Scholar
  63. E. Kerkelä, R. Ala-aho, L. Jeskanen et al., “Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers,” British Journal of Cancer, vol. 84, no. 5, pp. 659–669, 2001. View at Publisher · View at Google Scholar
  64. R. Mathew, R. Khanna, R. Kumar, M. Mathur, N. K. Shukla, and R. Ralhan, “Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications,” Cancer Detection and Prevention, vol. 26, no. 3, pp. 222–228, 2002. View at Publisher · View at Google Scholar
  65. P. J. Higgins, “TGF-β1-stimulated p21ras-ERK signaling regulates expression of the angiogenic SERPIN PAI-1,” Recent Research Developments in Biochemistry, vol. 7, pp. 31–45, 2006. View at Google Scholar
  66. S. M. Kutz, C. E. Higgins, R. Samarakoon et al., “TGF-ß1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling,” Experimental Cell Research, vol. 312, no. 7, pp. 1093–1105, 2006. View at Publisher · View at Google Scholar
  67. R. Samarakoon, C. E. Higgins, S. P. Higgins, S. M. Kutz, and P. J. Higgins, “Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-β1-stimulated smooth muscle cells is pp60c-src/MEK-dependent,” Journal of Cellular Physiology, vol. 204, no. 1, pp. 236–246, 2005. View at Publisher · View at Google Scholar
  68. P. P.-C. Hu, X. Shen, D. Huang, Y. Liu, C. Counter, and X.-F. Wang, “The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-β,” Journal of Biological Chemistry, vol. 274, no. 50, pp. 35381–35387, 1999. View at Publisher · View at Google Scholar
  69. M. Sato, K. Kawai-Kowase, H. Sato et al., “c-Src and hydrogen peroxide mediate transforming growth factor-ß1-induced smooth muscle cell-gene expression in 10T1/2 cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 2, pp. 341–347, 2005. View at Publisher · View at Google Scholar
  70. H. Sato, M. Sato, H. Kanai et al., “Mitochondrial reactive oxygen species and c-Src play a critical role in hypoxic response in vascular smooth muscle cells,” Cardiovascular Research, vol. 67, no. 4, pp. 714–722, 2005. View at Publisher · View at Google Scholar
  71. F. Viñals and J. Pouysségur, “Transforming growth factor β1 (TGF-β1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling,” Molecular and Cellular Biology, vol. 21, no. 21, pp. 7218–7230, 2001. View at Publisher · View at Google Scholar
  72. J. Guerrero, J. F. Santibañez, A. González, and J. Martínez, “EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases,” Experimental Cell Research, vol. 292, no. 1, pp. 201–208, 2004. View at Publisher · View at Google Scholar
  73. Y. Uchiyama-Tanaka, H. Matsubara, Y. Mori et al., “Involvement of HB-EGF and EGF receptor transactivation in TGF-ß-mediated fibronectin expression in mesangial cells,” Kidney International, vol. 62, no. 3, pp. 799–808, 2002. View at Publisher · View at Google Scholar
  74. L. Moro, L. Dolce, S. Cabodi et al., “Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines,” Journal of Biological Chemistry, vol. 277, no. 11, pp. 9405–9414, 2002. View at Publisher · View at Google Scholar
  75. J. S. Biscardi, M.-C. Maa, D. A. Tice, M. E. Cox, T.-H. Leu, and S. J. Parsons, “c-Src-mediated phosphorylation of the epidermal growth factor receptor on tyr845 and tyr1101 is associated with modulation of receptor function,” Journal of Biological Chemistry, vol. 274, no. 12, pp. 8335–8343, 1999. View at Publisher · View at Google Scholar
  76. C. K. Miranti and J. S. Brugge, “Sensing the environment: a historical perspective on integrin signal transduction,” Nature Cell Biology, vol. 4, no. 4, pp. E83–E90, 2002. View at Publisher · View at Google Scholar
  77. A. Alavi, J. D. Hood, R. Frausto, D. G. Stupack, and D. A. Cheresh, “Role of Raf in vascular protection from distinct apoptotic stimuli,” Science, vol. 301, no. 5629, pp. 94–96, 2003. View at Publisher · View at Google Scholar
  78. F. Chang, L. S. Steelman, J. T. Lee et al., “Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention,” Leukemia, vol. 17, no. 7, pp. 1263–1293, 2003. View at Publisher · View at Google Scholar
  79. A. Ziogas, K. Moelling, and G. Radziwill, “CNK1 is a scaffold protein that regulates Src-mediated Raf-1 activation,” Journal of Biological Chemistry, vol. 280, no. 25, pp. 24205–24211, 2005. View at Publisher · View at Google Scholar